Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Anita Archwamety"'
Autor:
Anita Archwamety, Nique Kunapinun, Sirinart Sirinvaravong, Piyaporn Apisarnthanarak, Charuwan Akewanlop, Krittiya Korphaisarn
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Scirrhous hepatocellular carcinoma (S-HCC) represents an uncommon subtype of HCC. During radiological evaluation this unique subtype is frequently mistaken as cholangiocarcinoma, fibrolamellar HCC, or metastatic adenocarcinoma. Here, we present the c
Externí odkaz:
https://doaj.org/article/51a00d5884c24f258189a6e3980d6261
Publikováno v:
Thoracic Cancer, Vol 13, Iss 17, Pp 2539-2541 (2022)
Abstract Here, we report a case of metastatic Epstein–Barr virus (EBV)‐related primary pulmonary lymphoepithelioma‐like carcinoma (PPLELC) in a young, nonsmoking female who responded well to treatment with two types of immune checkpoint inhibit
Externí odkaz:
https://doaj.org/article/278d0beb608a4e0d80c233d4be7f269e
Autor:
Anita Archwamety, Nattaya Teeyapun, Teerada Siripoon, Naravat Poungvarin, Suebpong Tanasanvimon, Ekaphop Sirachainan, Charuwan Akewanlop, Krittiya Korphaisarn
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundCurrent guidelines recommend anti-epidermal growth factor receptor monoclonal antibodies (anti-EGFR Ab) as first-line treatment only in patients with left-sided RAS wild type (RASwt) metastatic colorectal cancer (mCRC). However, there are n
Externí odkaz:
https://doaj.org/article/f93b82fc8322451c8cf7e1084cfcd615
Autor:
Anita Archwamety, Nattaya Teeyapun, Teerada Siripoon, Naravat Poungvarin, Suebpong Tanasanvimon, Ekaphop Sirachainan, Charuwan Akewanlop, Krittiya Korphaisarn
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundCurrent guidelines recommend anti-epidermal growth factor receptor monoclonal antibodies (anti-EGFR Ab) as first-line treatment only in patients with left-sided RAS wild type (RASwt) metastatic colorectal cancer (mCRC). However, there are n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6db6b853cdb8734a7d80fe67a4e264ec
https://doi.org/10.1200/jco.2022.40.4_suppl.195
https://doi.org/10.1200/jco.2022.40.4_suppl.195
Publikováno v:
Journal of Clinical Oncology. 39:3541-3541
3541 Background: The guideline recommends anti-EGFR monoclonal antibodies (anti-EGFR Ab) as first-line treatment only for patients with left-sided RAS wild type (RASwt) metastatic colorectal cancer (mCRC). However, there are no recommendations on tum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4068707b562f6d0f92a6e6d217f8d59d
https://doi.org/10.1200/jco.2021.39.15_suppl.3541
https://doi.org/10.1200/jco.2021.39.15_suppl.3541